GlobeNewswire

Nasdaq Financial Framework Technology Extended to Banks and Brokers Worldwide

Del

Technology will allow for trading infrastructure and operations outsourcing, as well as trade reporting;

Supports systematic internalizers, MTFs, OTFs, single dealer and algo trading platforms

STOCKHOLM, Sweden, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) announced its Market Technology division has now launched its Nasdaq Financial Framework technology into the banks and brokers segment for complete outsourcing of trading infrastructure and operations, including regulatory reporting. This new market infrastructure solution complements Nasdaq’s risk and surveillance technology offering, which, as the industry benchmark for trade surveillance, is leveraged by over 140 sell-side clients worldwide.

“With the Nasdaq Financial Framework, we are now able to extend the same exchange-grade technology and support used by our market operator clients to the sell-side, who are facing increased operational requirements and regulatory demands,” said Lars Ottersgård, Executive Vice President & Head of Market Technology, Nasdaq. “Our unique platform delivers technical scalability and flexibility along with the market operations expertise to support banks and brokers in running best-in-class technology while also focusing on growing their business.”

“Banks and Brokers have adapted their trading business models to the new regulatory requirements by sometimes offering a trading platform, whether an MTF, an OTF or a Systematic Internalizer (SI),” said Josephine Joséphine de Chazournes, Senior Analyst, Celent. “In this era of cost control they have also had to refocus their investments where the ROI is high and decided to outsource what others can do better or has become commoditized. The NFF platform can play a key role by offering Nasdaq’s market infrastructure technology to banks and brokers, including high end surveillance and regulatory reporting capabilities.”

Nasdaq Financial Framework for Banks & Brokers supports:

  • Systematic Internalizers: Continued regulatory pressure, specifically from MiFID II, has forced firms to determine their status as a Systematic Internalizer (SI). Under MiFID II, if firms’ activity exceeds certain thresholds, including equity and non-equity asset classes, they face additional regulatory obligations – including pre-trade transparency, quote and trade matching, best execution reporting and reference data reporting.
     
  • MTFs & OTFs:  Swift transaction speeds, trading incentives and lower costs have contributed to the growth of popularity in MTFs and soon OTFs throughout Europe. Also under MiFID II, both MTFs and OTFs face additional regulatory obligations – including systematic execution, best execution, pre-trade transparency, post-trade transparency, transaction reporting and regulatory requirements.
     
  • ATS/Single Dealer Platform: Investment banks are facing enhanced capital requirements as a result of the changing regulatory agenda. Increased data quantities, fragmented liquidity and inadequate technology resources are placing more pressure on sell-side firms to fundamentally reappraise their existing technology capabilities, requiring constant reinvestment to remain competitive.
     
  • Algo & Routing Infrastructure: Continued proliferation of trading venues has caused increased fragmentation in liquidity – placing additional pressure on firms’ routing systems to ensure optimal execution. To this end, firms must ensure their existing technology capabilities are up to par, continually investing to keep an edge.

“In launching this new offering, the sell-side industry can now leverage the Nasdaq Financial Framework for a range of endeavors, including setting up and running a full-scale, multi-lateral trading venue to addressing regulatory obligations for internalization,” said Carl Slesser, Vice President, Market Technology, Nasdaq. “We have built the platform to enable these services to be both deployed in the cloud and in our data warehouses, which allows for flexibility in terms of initial capacity and growth based on individual client requirements.”

Nasdaq’s world-leading market technology powers more than 250 of the world’s market infrastructure organizations and market participants, including broker-dealers, exchanges, clearinghouses, central securities depositories and regulators, in over 50 countries with end-to-end, mission-critical technology solutions.

NDAQG

About Nasdaq  

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 100 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 4,000 total listings with a market value of approximately $14 trillion. To learn more, visit: http://business.nasdaq.com

Media Contact

Ryan Wells
ryan.wells@nasdaq.com 
Mobile:  +44 (0) 7809 596 390

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t

CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00Pressemelding

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos

Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00Pressemelding

Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00Pressemelding

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated

GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12Pressemelding

SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00Pressemelding

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist